OMCL
HealthcareOmnicell, Inc. · Medical - Healthcare Information Services · $2B
What is Omnicell, Inc.?
Omnicell, Inc. develops medication management automation for hospitals, health systems, and pharmacies across the United States and internationally. The company focuses on reducing medication errors and improving pharmacy workflows through robotics and software.
Omnicell generates revenue by selling and supporting automated dispensing systems, central pharmacy robotics, and medication adherence packaging solutions. Hospitals and institutional pharmacies pay for hardware, software, and ongoing services that integrate with existing health information systems. The company also provides IV compounding robots, controlled substance management tools, and single-dose blister packaging equipment — targeting the full medication-use cycle from central pharmacy to patient bedside.
Omnicell was founded in 2001 and is headquartered in Mountain View, California.
- XT Series automated dispensing systems for nursing units and operating rooms
- XR2 Automated Central Pharmacy System for storage and retrieval
- IV compounding robots and workflow management software
- Single-dose blister packaging and medication adherence tools
- Omnicell Interface Software for health system integration
Is OMCL a Good Stock to Buy?
UQS Score rates OMCL as Below Average overall.
The strongest areas in OMCL's profile are Risk and Valuation, both rated Good. The Risk pillar suggests the company's financial structure carries a manageable level of near-term concern relative to peers, while the Valuation pillar indicates the stock is not trading at a significant premium — potentially offering a more accessible entry point compared to higher-rated healthcare automation names.
Quality, Moat, and Growth all carry Weak ratings, pointing to meaningful challenges in profitability, competitive differentiation, and revenue expansion that investors should weigh carefully.
See the exact pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does OMCL pay dividends?
No — Omnicell, Inc. does not currently pay a dividend.
Omnicell does not currently pay a dividend. Companies at this stage of the healthcare technology lifecycle typically reinvest available capital into product development, sales infrastructure, and integration capabilities rather than returning cash to shareholders. Investors seeking income from this sector may need to look elsewhere.
When does OMCL report earnings?
Omnicell reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's Growth pillar is rated Weak, reflecting a period of muted top-line expansion and profitability pressure. Execution on its automation platform and services transition remains a key area to monitor each reporting cycle.
For the most recent quarter's results and guidance, visit Omnicell's official investor relations page.
OMCL Price History
-73.6% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Omnicell, Inc.?
Based on Omnicell, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
OMCL Long-term Outlook
OMCL's fundamental outlook is shaped by Weak Growth and Weak Quality pillar ratings, suggesting the near-term path to meaningful earnings improvement faces real headwinds. The Good Risk rating provides some stability, indicating the balance sheet is not under acute stress. The Good Valuation rating means the stock may already reflect a degree of pessimism, which could limit downside if operational trends stabilize. Sustained improvement in the Quality and Growth pillars would be the clearest signal of a turning point.
Growth drivers
- Ongoing hospital demand for pharmacy automation and error-reduction technology
- Expansion of central pharmacy robotics and software-as-a-service offerings
- International market penetration for medication management platforms
Key risks
- Weak profitability metrics limiting reinvestment capacity
- Competitive pressure from larger, better-capitalized healthcare technology vendors
- Slow enterprise sales cycles and budget constraints at health system customers
OMCL vs Peers
Omnicell operates in a broader healthcare technology landscape alongside companies addressing different aspects of clinical and pharmacy workflows.
GeneDx focuses on genomic and rare disease diagnostics rather than pharmacy automation, serving a distinct clinical need within healthcare.
Progyny delivers fertility benefits management solutions for employers, operating in a specialty benefits niche separate from medication dispensing.
Heartflow applies computational modeling to cardiovascular diagnostics, competing for healthcare IT budgets in a different clinical domain than Omnicell.
Frequently Asked Questions
What does Omnicell do?
Omnicell provides medication management automation for hospitals and pharmacies. Its products include automated dispensing cabinets, central pharmacy robotics, IV compounding systems, and medication adherence packaging — all designed to reduce errors and streamline the medication-use process from central pharmacy to patient care areas.
Does OMCL pay dividends?
Omnicell does not currently pay a dividend. The company has historically directed capital toward its automation platform and service capabilities rather than shareholder distributions. Income-focused investors should factor this into their assessment.
When does OMCL report earnings?
Omnicell follows a standard quarterly earnings cadence for US-listed companies. Specific dates are not covered by our data source — check Omnicell's investor relations page for the current reporting schedule and upcoming calls.
Is OMCL a good stock to buy?
UQS Score rates OMCL as Below Average, driven by Weak ratings across Quality, Moat, and Growth. The Good Risk and Valuation ratings offer some offset. Whether it fits a portfolio depends on individual risk tolerance and investment goals — the full pillar breakdown is available to Pro members.
Is OMCL overvalued?
The UQS Valuation pillar for OMCL is rated Good, suggesting the stock is not trading at an elevated premium relative to its fundamentals. That said, a reasonable valuation does not automatically compensate for weak quality or growth characteristics — context across all five pillars matters.
How does OMCL compare to its competitors?
Omnicell occupies a specific niche in pharmacy automation that differs from peers like GeneDx, Progyny, and Heartflow, which address genomics, fertility benefits, and cardiovascular diagnostics respectively. Direct feature-for-feature comparisons are limited given these distinct business models. UQS Score pillar comparisons are available for Pro members.
What is OMCL's market cap bracket?
Omnicell is classified as a small-cap company. This places it in a segment of the market that can offer growth potential but also carries higher volatility and liquidity risk compared to large- or mega-cap healthcare technology peers.
Who founded Omnicell?
Omnicell's founding history and leadership background are widely available through the company's official website and public filings. The company has been operating since 2001 and is headquartered in Mountain View, California.
Is OMCL a long-term quality indicator?
From a long-term quality standpoint, OMCL's current UQS profile — with Weak ratings in Quality, Moat, and Growth — signals that the business has not yet demonstrated the durable competitive advantages and consistent profitability typically associated with high-conviction long-term holdings. Monitoring pillar trends over time is advisable.
What is the main competitive advantage of Omnicell?
Omnicell's potential advantage lies in its integrated platform spanning dispensing, central pharmacy robotics, and software — creating switching costs once embedded in a health system's workflow. However, the UQS Moat pillar is currently rated Weak, suggesting this advantage has not yet translated into measurable durable differentiation.
What sector does OMCL belong to?
Omnicell operates in the Healthcare sector, specifically within healthcare technology and pharmacy automation. It serves hospitals, health systems, and institutional pharmacies, making it sensitive to healthcare capital spending cycles and regulatory dynamics.
Unlock Full OMCL Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access underlying financial metrics driving each pillar
- ✓Compare OMCL against sector peers side by side
- ✓Track pillar changes across reporting periods
- ✓Screen for stocks with stronger Quality and Moat ratings
Pro Analysis
OMCL — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 21, 2026 | 43.5 | 27.4 | 31.0 | 36.3 | 78.9 | 65.2 | +4.0 |
| May 7, 2026 | 39.5 | 22.6 | 31.0 | 36.3 | 61.1 | 64.7 | 0.0 |
| May 3, 2026 | 39.5 | 22.2 | 31.0 | 36.3 | 61.1 | 65.0 | -0.5 |
| May 1, 2026 | 40.0 | 22.2 | 31.0 | 36.3 | 61.1 | 68.6 | +0.2 |
| Apr 26, 2026 | 39.8 | 22.2 | 31.0 | 35.7 | 61.1 | 68.0 | +0.1 |
| Apr 19, 2026 | 39.7 | 22.2 | 31.0 | 35.7 | 61.1 | 67.1 | -0.4 |
| Apr 18, 2026 | 40.1 | 22.2 | 31.0 | 35.7 | 61.1 | 69.8 | -1.5 |
| Apr 14, 2026 | 41.6 | 22.2 | 31.0 | 35.7 | 61.1 | 80.1 | -0.1 |
| Apr 12, 2026 | 41.7 | 22.2 | 31.0 | 35.7 | 61.1 | 80.7 | 0.0 |
| Apr 11, 2026 | 41.7 | 22.2 | 31.0 | 35.7 | 61.1 | 80.9 | 0.0 |
OMCL — Pillar Breakdown
Quality
— 27.2/100 (25%)Omnicell, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 36.3/100 (20%)Omnicell, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 78.9/100 (15%)Omnicell, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 63.5/100 (15%)Omnicell, Inc. trades at a reasonable valuation with decent earnings yield and FCF multiples.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 31/100 (25%)Omnicell, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for OMCL.
Score Composition
Financial Data
More Stock Analysis
How is the OMCL UQS Score Calculated?
The UQS (Unified Quality Score) for Omnicell, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Omnicell, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Omnicell, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.